Why chronic myeloid leukaemia cannot be cured by tyrosine kinase-inhibitors

Leukemia. 2021 Aug;35(8):2199-2204. doi: 10.1038/s41375-021-01272-8. Epub 2021 May 17.

Authors

Michele Baccarani¹, Robert Peter Gale²

Affiliations

¹ Department of Hematology, "L. and A Seràgnoli" University of Bologna and St.Orsola-Malpighi University Hospital, Bologna, Italy. michele.baccarani@unibo.it.
² Haematology Research Centre, Department of Immunology and Inflammation, Imperial College London, London, UK.

PMID: 34002028
DOI: 10.1038/s41375-021-01272-8

No abstract available

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Fusion Proteins, bcr-abl / antagonists & inhibitors
Fusion Proteins, bcr-abl / genetics*
Fusion Proteins, bcr-abl / metabolism
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
Molecular Targeted Therapy / standards*
Protein Kinase Inhibitors / therapeutic use*

Substances

Protein Kinase Inhibitors
Fusion Proteins, bcr-abl